Middle East and Africa Pulmonary Function Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Middle East and Africa Pulmonary Function Testing Market Size

• The Middle East and Africa pulmonary function testing market size was valued at USD 172.26 million in 2024 and is expected to reach USD 237.57 million by 2032, at a CAGR of 4.10% during the forecast period
• The market growth is largely fueled by the increasing burden of respiratory diseases such as asthma, COPD, and tuberculosis, combined with heightened awareness of early lung function screening and diagnosis across the region
• Furthermore, rising government healthcare spending, along with the expansion of diagnostic infrastructure and private sector investments, is establishing pulmonary function testing as a key clinical tool in respiratory care. These converging factors are accelerating the adoption of pulmonary diagnostic technologies, thereby significantly boosting the industry’s growth

Middle East and Africa Pulmonary Function Testing Market Analysis

• Pulmonary function testing (PFT), encompassing a range of diagnostic procedures to evaluate lung function and respiratory health, is becoming increasingly essential in healthcare systems across the Middle East and Africa due to the growing burden of chronic respiratory diseases and heightened clinical focus on early detection and management
• The escalating demand for pulmonary function testing is primarily fueled by increasing cases of asthma, COPD, and occupational lung disorders, combined with rising public awareness and governmental initiatives promoting respiratory health screening
• South Africa dominated the Middle East and Africa pulmonary function testing market with the largest revenue share of 39.2% in 2024, supported by improved access to diagnostic care, national respiratory health campaigns, and investments in upgrading medical technologies across both urban and rural healthcare facilities
• Saudi Arabia is expected to be the fastest growing country in the pulmonary function testing market during the forecast period due to rising healthcare investments, increasing prevalence of lifestyle-related respiratory conditions, and expanding diagnostic infrastructure
• The hardware segment dominated the pulmonary function testing market with a market share of 49.8% in 2024, driven by the widespread use of spirometers and plethysmographs across hospitals and specialty clinics for routine respiratory diagnostics and disease monitoring

Report Scope and Middle East and Africa Pulmonary Function Testing Market Segmentation

Middle East and Africa Pulmonary Function Testing Market Trends

Technology-Enabled Respiratory Diagnostics and Remote Monitoring

• A significant and accelerating trend in the Middle East and Africa pulmonary function testing market is the integration of digital technologies and remote diagnostic capabilities in pulmonary devices, improving accessibility and efficiency in respiratory care
  • For instance, companies are introducing portable and connected spirometers that allow real-time data transmission to healthcare providers, facilitating remote monitoring for patients with chronic conditions such as asthma and COPD, particularly in underserved or rural regions
• The rise of telehealth platforms has further enhanced the utility of digitally integrated pulmonary function tests, enabling clinicians to interpret lung function results remotely and provide timely interventions, especially crucial in areas with limited specialist access
• AI-based software is increasingly being utilized to automate lung function test interpretation, reduce diagnostic errors, and support clinical decision-making by analyzing large volumes of patient data for patterns suggestive of early-stage respiratory disorders
• In response to the need for continuity of care, companies such as Vitalograph and NuvoAir are actively developing compact and user-friendly devices that support home-based testing and integrate with mobile apps for patient engagement and data sharing with physicians
• This trend toward technologically advanced, mobile, and intelligent pulmonary testing solutions is reshaping respiratory diagnostics in the region, supporting earlier diagnosis, patient-centric care models, and improved management of chronic respiratory diseases

Middle East and Africa Pulmonary Function Testing Market Dynamics

Driver

Rising Respiratory Disease Burden and Expanding Diagnostic Infrastructure

• The growing incidence of chronic respiratory diseases such as COPD, asthma, and pulmonary fibrosis, driven by factors such as air pollution, smoking, and occupational hazards, is a major driver for the adoption of pulmonary function testing across the region
  • For instance, in countries such as South Africa and Egypt, the high burden of tuberculosis and increasing rates of asthma have led to the inclusion of pulmonary testing in national healthcare protocols, boosting market growth
• Governments and private healthcare providers are expanding access to diagnostic services through investments in specialized respiratory care units, mobile testing programs, and awareness campaigns that promote early screening
• The increasing availability of trained pulmonologists and technicians, along with collaborations between public health departments and private diagnostic firms, is enhancing the penetration of pulmonary function testing technologies in urban and semi-urban areas
• In addition, the shift toward preventive healthcare and the emphasis on non-invasive, cost-effective diagnostic methods are further fueling demand, as spirometry and other PFT modalities provide critical insights into lung health with minimal risk to patients

Restraint/Challenge

Lack of Skilled Workforce and Accessibility Barriers in Remote Areas

• A key challenge in the Middle East and Africa pulmonary function testing market is the limited availability of trained personnel to administer and interpret tests, particularly in low-resource or rural settings, where healthcare infrastructure remains underdeveloped
  • For instance, despite increased demand, many healthcare facilities in sub-Saharan regions lack the specialized respiratory staff or equipment needed to perform comprehensive lung function assessments
• This skills gap leads to underutilization of pulmonary testing equipment and can result in delayed diagnosis and suboptimal disease management, especially in populations with high vulnerability to respiratory illnesses
• In addition, the high cost of advanced PFT devices and maintenance, combined with logistical challenges in device deployment across remote locations, continues to impede wider adoption
• Overcoming these issues through strategic investments in training programs, government incentives for healthcare modernization, and the deployment of mobile or handheld diagnostic units will be essential for bridging accessibility gaps and sustaining market growth across diverse healthcare landscapes

Middle East and Africa Pulmonary Function Testing Market Scope

The market is segmented on the basis of type, patient type, application, and end user.

• By Type

On the basis of type, the Middle East and Africa pulmonary function testing market is segmented into hardware, services, and software. The hardware segment dominated the market with the largest revenue share of 49.8% in 2024, driven by the widespread adoption of spirometers, plethysmographs, and gas diffusion systems across hospitals and diagnostic laboratories. These devices form the core components of pulmonary function testing, offering accurate and real-time lung performance data. Investments in modernizing healthcare facilities and expanding diagnostic capacity across South Africa, Saudi Arabia, and the UAE are further fueling the demand for hardware-based solutions.

The software segment is expected to witness the fastest growth rate from 2025 to 2032, propelled by the growing trend of digitized diagnostics and AI-based interpretation. Software advancements now allow seamless integration with hospital systems, remote data access, and automated test result analysis enhancing diagnostic efficiency and clinical decision-making.

• By Patient Type

On the basis of patient type, the pulmonary function testing market is segmented into pediatric, adult, and geriatric. The adult segment accounted for the largest market share in 2024 due to the higher prevalence of chronic obstructive pulmonary disease (COPD), asthma, and occupational respiratory disorders among working-age individuals. The rise in tobacco use, industrial exposure, and urban air pollution across the region has made pulmonary function testing essential for adults, particularly in urban medical settings.

The geriatric segment is projected to grow at the fastest CAGR during the forecast period. Aging populations across the region, especially in countries such as South Africa and Egypt, are increasingly susceptible to restrictive lung diseases and age-related pulmonary decline, necessitating regular lung function assessment.

• By Application

On the basis of application, the pulmonary function testing market is segmented into obstructive lung disease and restrictive lung disease. The obstructive lung disease segment dominated the market in 2024, fueled by the widespread burden of asthma, COPD, and bronchitis across both urban and rural populations. Public health campaigns and early detection programs are driving increased pulmonary screening for such conditions.

The restrictive lung disease segment is expected to grow significantly during forecast period, due to rising awareness and diagnosis of interstitial lung diseases and post-TB lung function impairments. Increasing referrals for pulmonary rehabilitation and follow-up care also contribute to the segment’s expansion.

• By End User

On the basis of end user, the pulmonary function testing market is segmented into hospitals, specialty clinics, diagnostics laboratories, home care settings, and others. The hospital segment dominated the market with the highest revenue contribution in 2024, owing to the availability of advanced diagnostic infrastructure, skilled personnel, and funding for equipment procurement. Government and private hospitals across the region are increasingly integrating PFTs into routine respiratory screening and chronic disease management protocols.

The home care settings segment is anticipated to experience the fastest growth from 2025 to 2032, driven by rising demand for portable and user-friendly spirometry devices. As remote monitoring and telehealth platforms gain popularity, especially in managing chronic lung conditions, at-home pulmonary testing is becoming a critical component of decentralized healthcare delivery in the region.

Middle East and Africa Pulmonary Function Testing Market Regional Analysis

• South Africa dominated the Middle East and Africa pulmonary function testing market with the largest revenue share of 39.2% in 2024, supported by improved access to diagnostic care, national respiratory health campaigns, and investments in upgrading medical technologies across both urban and rural healthcare facilities
• Healthcare providers in the region are increasingly prioritizing early diagnosis and routine lung function screening, supported by government initiatives and awareness campaigns targeting chronic respiratory conditions
• This strong demand is further reinforced by the availability of skilled healthcare professionals, improved access to healthcare facilities in urban centers, and the adoption of portable diagnostic technologies, positioning pulmonary function testing as a key tool in respiratory care management across the country

The South Africa Pulmonary Function Testing Market Insight

The South Africa pulmonary function testing market captured the largest revenue share of 39.2% in 2024 within the region, fueled by a high burden of tuberculosis, asthma, and smoking-related diseases. Investments in diagnostic infrastructure by both government and private healthcare providers are expanding access to lung testing across hospitals and clinics. National screening campaigns, especially in urban areas, and the integration of PFT into routine care protocols are significantly boosting market penetration.

Saudi Arabia Pulmonary Function Testing Market Insight

The Saudi Arabia pulmonary function testing market is projected to expand at a substantial CAGR throughout the forecast period, supported by strategic healthcare modernization initiatives under the Saudi Vision 2030 framework. Increasing demand for early respiratory disease detection, expanding insurance coverage, and investment in digital healthcare infrastructure are fostering the adoption of advanced pulmonary diagnostic tools in hospitals and specialty clinics across the Kingdom.

United Arab Emirates Pulmonary Function Testing Market Insight

The UAE pulmonary function testing market is anticipated to grow at a noteworthy CAGR throughout the forecast period, driven by its rapidly advancing healthcare infrastructure and high prevalence of lifestyle-related respiratory illnesses. With a focus on preventive healthcare, the UAE is witnessing a surge in the deployment of portable PFT devices and AI-driven diagnostic platforms in private healthcare networks. Government-led initiatives to tackle air quality issues and promote health screening are further accelerating market growth.

Egypt Pulmonary Function Testing Market Insight

The Egypt pulmonary function testing market is expected to grow steadily during the forecast period, driven by increased government investment in public health and a growing awareness of chronic respiratory conditions such as asthma and COPD. The expansion of diagnostic services into rural and underserved regions, along with the adoption of affordable testing solutions, is helping to improve access to pulmonary care and drive demand for PFT devices in both public and private sectors.

Middle East and Africa Pulmonary Function Testing Market Share

The Middle East and Africa pulmonary function testing industry is primarily led by well-established companies, including:

• MGC Diagnostics Corporation (U.S.)
• Vyaire Medical, Inc. (U.S.)
• Schiller AG (Switzerland)
• COSMED Srl (Italy)
• BD (U.S.)
• NDD Medical Technologies AG (Switzerland)
• Medisoft SA (Belgium)
• Jones Medical Instrument Company (U.S.)
• Vitalograph Ltd. (U.K.)
• Futuremed America Inc. (U.S.)
• Thor Medical Systems (Israel)
• Sibelmed (Spain)
• Koko, LLC (nSpire Health) (U.S.)
• Labtech Ltd. (Hungary)
• Spirohome (Biyofarma Biomedical) (Turkey)
• Masimo Corporation (U.S.)
• EOVE (France)
• SensorMedics Corporation (U.S.)
• SDI Diagnostics (U.S.)

What are the Recent Developments in Middle East and Africa Pulmonary Function Testing Market?

• In May 2024, Vitalograph, a global respiratory diagnostics company, partnered with a major healthcare group in South Africa to deploy a new generation of portable spirometry devices across public hospitals. This initiative is aimed at improving early detection of chronic respiratory conditions, particularly in underserved regions. The deployment highlights Vitalograph’s commitment to enhancing lung health monitoring through reliable and accessible technology, tailored to the region’s unique healthcare challenges
• In April 2024, the Egyptian Ministry of Health launched a nationwide respiratory screening program incorporating advanced pulmonary function testing as part of its early detection and chronic disease management strategy. By integrating spirometry and lung volume measurement tools into primary care clinics, the initiative seeks to combat rising rates of asthma and COPD. This development reflects the government’s focus on preventive care and strengthening respiratory diagnostics infrastructure
• In March 2024, Schiller AG expanded its distribution network in the Middle East by collaborating with local healthcare providers in the UAE and Saudi Arabia. The expansion includes the rollout of multifunctional pulmonary function testing systems with integrated ECG and vital signs monitoring. The move is designed to support comprehensive diagnostics in cardiopulmonary departments and reinforce Schiller’s presence in the fast-growing MEA diagnostics market
• In February 2024, the University of KwaZulu-Natal in South Africa partnered with an international research consortium to study long-term pulmonary impairment post-tuberculosis treatment. The project involves large-scale deployment of digital PFT devices for community-level testing and data collection. This research effort emphasizes the growing importance of pulmonary function testing in both clinical and academic settings across Africa
• In January 2024, Vyaire Medical, Inc. announced the launch of its Vyntus BODY system in selected hospitals across the GCC region. Designed for advanced lung volume measurements, this system aims to provide accurate diagnostics for patients with restrictive and obstructive lung conditions. The introduction of Vyntus BODY reinforces Vyaire’s strategic focus on high-performance pulmonary diagnostics tailored to the needs of MEA healthcare providers

SKU-72776